Sign inJoin waitlistJoin the waitlist

Kasiani Myers

Professor of Clinical-Affiliate · University of Cincinnati Medical Center Inc.

Credentials: · · ·

History

University of Cincinnati Medical Center Inc.
Present
Cincinnati Children's Hospital Medical Center
Present
Cincinnati Children's Hospital Medical Center
Present

Pediatric Hematology-Oncology
2007–2008
Pediatrics
2004–2007
Case Western Reserve Univ Sch of Med
2000–2004
University of Michigan, Ann Arbor, MI, 2000
1996–2000

Research

Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults
Blood · 2014 · 346 citations
A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury
Review · Blood Reviews · 2015 · 267 citations
On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology
Nature Biomedical Engineering · 2020 · 221 citations

Stella Davies
98 papers
Sonata Jodele
53 papers
Christopher Dandoy
44 papers · 7 as a fellow
Parinda Mehta
39 papers
JE
Javier El-Bietar
28 papers
Akiko Shimamura
25 papers
GW
Gregory Wallace
24 papers
AN
Adam Nelson
21 papers · 10 as a resident
Jane Koo
21 papers · 2 as a fellow
Seth Rotz
21 papers · 5 as a fellow
Michael Grimley
14 papers
Pooja Khandelwal
14 papers · 1 as a fellow

Grants

Penetrating the “Black Box”: Prediction of Early Bronchiolitis Obliterans in Pediatric Hematopoietic Stem Cell Transplant Recipients
National Heart, Lung, and Blood Institute · R01
Contact PI · $3.1M · Cincinnati Childrens Hosp Med Ctr
2021–2027

Clinical trials

Rollover Study From EXG-US-01
Principal investigator · Enrolling by invitation · Phase 1
Elixirgen Therapeutics, Inc.
2024–2027
Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
Principal investigator · Terminated · Phase 2
Children's Hospital Medical Center, Cincinnati
2021–2025
Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure
Principal investigator · Active not recruiting · Phase 1
Elixirgen Therapeutics, Inc.
2021–2027